Job Trends
The latest round of layoffs comes just two months after Thermo Fisher announced plans to close three sites in San Diego, bringing the total to nearly 600 jobs cut in 2023.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Career Advice
Many job seekers take it for granted that the holidays are not the best time to be on the job market, so they suspend their job hunt until after the new year. Others get distracted by all of the holiday hullabaloo and don’t put as much time and effort into their search as they need to.
THE LATEST
Merck Chief Executive Officer Kenneth C. Frazier is stepping down from his role atop the helm of the pharma giant on June 30 after nearly 30 years with the company.
As the therapy “did not achieve proof-of-concept” and failed to provide benefit in this study, the development of the drug has been discontinued.
Amgen released its fourth-quarter and full-year 2020 results today and although there was good news financially, there was also news of five cancer programs that have either been halted or abandoned.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
Although designed for two doses, primary analysis of AstraZeneca and the University of Oxford’s Phase III data for its COVID-19 vaccine found it to have 76% efficacy after the first dose.
MOMA Therapeutics and Eli Lilly are both experiencing significant changes in their leadership roster, with one Takeda alum taking the helm at MOMA and an R&D chief at Lilly shooting toward the exit door.
Adding Yervoy to the therapy did not improve overall survival (OS) or progression-free survival (PFS) but did add toxicity to Keytruda monotherapy.
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
It was a busy week for clinical trial news. Read on for more information.